A recent study revealed that by using standardized uptake value thresholds as determined by 2-[18F]-FDG PET/CT, investigators were able to predict the occurrence of Richter syndrome in patients with CLL.
An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.
This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.